Basic Information
| LncRNA/CircRNA Name | LINC00174 |
| Synonyms | NA |
| Region | GRCh38_7:66376044-66493566 |
| Ensemble | ENSG00000179406 |
| Refseq | NR_026873 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, RIP, etc. |
| Sample | glioma tissues, glioma cell lines (U251, LN229, H4, SW1783, and A172) and human embryonic kidney cell line HEK-293 T |
| Expression Pattern | up-regulated |
| Function Description | LINC00174 was overexpressed in glioma tissues and cell lines. LINC00174 knockdown inhibited cell proliferation, migration, invasion and glycolysis of glioma cells, and LINC00174 exerted a tumorigenesis role. LINC00174 could interact with miR-152-3p/SLC2A1 axes. The miR-152-3p inhibitor or the SLC2A1 overexpression could rescue the anti-tumor effect of LINC00174 knockdown on glioma cells. Moreover, downregulation of LINC00174 also inhibited tumor volume and delayed the tumor growth in vivo. |
| Pubmed ID | 31492194 |
| Year | 2019 |
| Title | Long non-coding RNA LINC00174 promotes glycolysis and tumor progression by regulating miR-152-3p/SLC2A1 axis in glioma |
External Links
| Links for LINC00174 | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |